title: Patterns of Use and Short-Term Outcomes of Minimally Invasive Surgery for Malignant Pheochromocytoma: A Population-Level Study.
abstract: BACKGROUND
  Malignant pheochromocytoma is rare, and there is a scarcity of data on the use of minimally invasive surgery (MIS) for treatment. The aims of this study were to analyze patterns of use of MIS for malignant pheochromocytoma in the U.S. and compare short-term outcomes to those of open adrenalectomy.
  
  
  METHODS
  Patients with malignant pheochromocytoma undergoing MIS, including laparoscopy, robotic assisted, laparoscopy converted to open, or open adrenalectomy, were culled from the National Cancer Database, from 1998 to 2011. Data were examined using simple summary statistics, Χ2 and student's t tests, Mann-Whitney test, and logistic regression.
  
  
  RESULTS
  A total of 36 MIS and 67 open adrenalectomies were identified in 2010-2011. No significant differences were observed between the two treatment groups in demographic characteristics or comorbidities. Preoperative diagnosis of malignancy was made in 52.8% of MIS and 48.5% of open patients (p=NS). MIS and open adrenalectomies did not differ with respect to lymph node metastases, vascular invasion, extra-adrenal-extension, and distant metastases (all p=NS). MIS tended to more often be used to perform partial adrenalectomy (38.9 vs. 20.4% open, p=0.061); surgical margins, 30-day readmission and mortality rates were similar to open adrenalectomy (all p=NS). Tumors removed via MIS were smaller (48.7 vs. 73.3 mm open, p=0.003) and associated with a shorter length of stay.
  
  
  CONCLUSIONS
  A significant proportion of patients with malignant pheochromocytomas underwent MIS, with short-term outcomes which are comparable to those of open surgery. Further studies focused on long-term survival and recurrence are needed to assess the role of MIS in the management of these rare tumors.
authors.affiliation: Duke Clinical Research Institute, Durham, NC, USA.
authors.forename: P
authors.initials: P
authors.lastname: Goffredo
authors.forename: M A
authors.initials: MA
authors.lastname: Adam
authors.forename: S M
authors.initials: SM
authors.lastname: Thomas
authors.forename: R P
authors.initials: RP
authors.lastname: Scheri
authors.forename: J A
authors.initials: JA
authors.lastname: Sosa
authors.forename: S A
authors.initials: SA
authors.lastname: Roman
mesh_terms: D000310:Adrenal Gland Neoplasms / Q000473:pathology / Q000601:surgery*; D000315:Adrenalectomy / Q000379:methods* / Q000706:statistics & numerical data; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D016208:Databases, Factual; D005260:Female; D006801:Humans; D010535:Laparoscopy / Q000379:methods / Q000706:statistics & numerical data; D007902:Length of Stay / Q000706:statistics & numerical data; D008207:Lymphatic Metastasis; D008297:Male; D008875:Middle Aged; D019060:Minimally Invasive Surgical Procedures / Q000379:methods / Q000706:statistics & numerical data; D009364:Neoplasm Recurrence, Local / Q000473:pathology; D010359:Patient Readmission / Q000706:statistics & numerical data; D010673:Pheochromocytoma / Q000473:pathology / Q000556:secondary / Q000601:surgery*; D012189:Retrospective Studies; D016896:Treatment Outcome; D014481:United States
references.citation: Surgery. 2001 Dec;130(6):1072-7
references.pmid: 11742341
references.citation: Acta Chir Belg. 2013 May-Jun;113(3):203-7
references.pmid: 24941717
references.citation: Langenbecks Arch Surg. 2012 Feb;397(2):239-46
references.pmid: 22069042
references.citation: Int J Urol. 2008 Apr;15(4):295-8
references.pmid: 18380814
references.citation: Kaohsiung J Med Sci. 2009 Aug;25(8):438-44
references.pmid: 19605338
references.citation: Urology. 2014 Jun;83(6):1225-32
references.pmid: 24642075
references.citation: Surg Endosc. 2008 Mar;22(3):617-21
references.pmid: 18071798
references.citation: Am J Surg. 2011 May;201(5):700-8
references.pmid: 20870212
references.citation: Br J Surg. 2012 Dec;99(12):1639-48
references.pmid: 23023976
references.citation: J Endourol. 2014 Jan;28(1):56-60
references.pmid: 23941419
references.citation: Ann Surg Oncol. 2010 Jan;17(1):4-7
references.pmid: 19847564
references.citation: Curr Opin Urol. 2008 Mar;18(2):134-8
references.pmid: 18303532
references.citation: J Visc Surg. 2011 Sep;148(4):e250-61
references.pmid: 21820984
references.citation: Cir Cir. 2013 May-Jun;81(3):196-201
references.pmid: 23769247
references.citation: J Cancer Res Clin Oncol. 2001;127(3):143-55
references.pmid: 11260859
references.citation: Ann Surg Oncol. 2013 Dec;20(13):4190-4
references.pmid: 23864309
references.citation: J Surg Oncol. 2013 May;107(6):659-64
references.pmid: 23233320
references.citation: BMC Surg. 2013;13 Suppl 2:S5
references.pmid: 24267584
references.citation: Surg Oncol Clin N Am. 2013 Jan;22(1):111-24, vi-vii
references.pmid: 23158088
references.citation: Surgeon. 2013 Oct;11(5):253-7
references.pmid: 23414734
references.citation: Am Surg. 2011 Apr;77(4):409-16
references.pmid: 21679547
references.citation: Surg Endosc. 2013 Jul;27(7):2321-6
references.pmid: 23355166
references.citation: J Clin Endocrinol Metab. 2014 Dec;99(12):E2681-5
references.pmid: 25188716
references.citation: J Clin Endocrinol Metab. 2007 Apr;92(4):1217-25
references.pmid: 17284633